Flexion Therapeutics (NASDAQ:FLXN) announced its earnings results on Thursday. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.01, Fidelity Earnings reports. The company had revenue of $21.79 million during the quarter, compared to analyst estimates of $18.85 million. Flexion Therapeutics had a negative net margin of 368.31% and a negative return on equity of 175.29%.
Shares of FLXN traded down $0.69 during mid-day trading on Friday, reaching $16.43. The stock had a trading volume of 1,132,400 shares, compared to its average volume of 622,178. Flexion Therapeutics has a 12 month low of $8.76 and a 12 month high of $17.82. The firm has a market cap of $655.05 million, a price-to-earnings ratio of -3.66 and a beta of 1.38. The company has a debt-to-equity ratio of 3.95, a quick ratio of 7.33 and a current ratio of 7.80. The business has a fifty day moving average of $14.85 and a 200 day moving average of $12.36.
A number of equities analysts have weighed in on FLXN shares. BidaskClub upgraded shares of Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 5th. Northland Securities set a $20.00 price target on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 10th. ValuEngine lowered shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Finally, Zacks Investment Research lowered shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 8th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Flexion Therapeutics presently has an average rating of “Buy” and an average price target of $23.57.
About Flexion Therapeutics
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Story: How to invest using market indexes
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.